Financing ·
OSR Health amends license deal to allow $15M convertible note issuance as alternative to equity option
OSRHWOSR Health, Inc.
OSR Health, Inc. entered into Amendment No. 1 to its Global Exclusive License Agreement with BCM Europe AG, creating a Convertible Note Option to settle the existing Equity Option. This change follows Nasdaq's delisting determination for OSRH common stock on August 19, 2026. The amendment allows OSR Health to issue up to $15 million in aggregate principal amount of convertible notes, issued in four tranches of $3.75 million each. These notes are convertible into common stock at fixed prices of approximately $2.00, $3.00, $4.00, and $5.00 per share, subject to Nasdaq's Minimum Price rule. BCM Europe AG must deliver a binding commitment from a purchaser with the election notice, with closing occurring no fewer than twenty business days after notice. If closing fails within ten business days of the scheduled date, the option reverts to equity settlement. OSR Health operates in the biopharmaceutical industry, focusing on vaccine development and immunotherapy.